Axtria, Inc., a global leader of award-winning cloud software and an integrated analytics solutions provider with deep experience in real-world evidence (RWE) and health economics and outcomes research (HEOR), will present at ISPOR 2024.
The Professional Society for Health Economics and Outcomes Research (ISPOR) will hold its ISPOR 2024 conference on May 5–8, 2024 in Atlanta, GA. The conference will unite industry and academic researchers, policymakers, regulators, payers, patient representatives, and other healthcare stakeholders to explore the latest issues in RWE and HEOR.
Axtria’s David Hood, Senior Manager, RWE and HEOR, will present “Patients’ Perspectives on Muscular Dystrophy: Insights from Social Media Listening.” In addition, Coby Martin, Project Leader, HEOR and Evidence Synthesis, will present “Targeted Literature Review of the Use of Real-World Evidence from Single Real-World Data and Sources in Meta-Analyses: Methodologies and Recommendations from HTA Bodies.”
“We eagerly anticipate sharing our pioneering insights and strategies in real-world evidence and health economics outcomes research,” said Won Chan Lee, Ph.D., Principal, Practice Lead of RWE, HEOR, and Evidence Synthesis Practice at Axtria. “As a leader in this field, Axtria is committed to advancing healthcare through innovation and collaboration, and we look forward to engaging with peers and industry experts at this prestigious event."
Axtria will present the following posters at ISPOR 2024:
-
Anhedonia-Related Wording in Social Media: An Application of Natural Language Processing
-
Use of External Control Arms in Novel Drug Approvals by U.S. Food and Drug Administration: A Targeted Review
-
Predictive Horizons: Unveiling Cardiovascular Insights with Conditional Inference Trees
-
Comparing Predictive Models: Traditional vs. Modern Statistical Approaches for Economic Outcomes in Major Depressive Disorder
-
A Cost-Effectiveness Analysis of Intrauterine Spacers Used to Prevent the Formation of Intrauterine Adhesions Following Endometrial Cavity Surgery
-
An updated landscape of FDA-approved Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices from 1995-2023
-
The Use of Natural Language Processing in Literature Reviews
-
Novel Drug Approvals By the U.S. Food and Drug Administration in Rare Diseases: Findings from 2020–2023
-
Burden of Illness of Intrauterine Adhesions Following Intrauterine Procedures: A Retrospective Analysis of Real-World Data
Meet our RWE and HEOR experts at Booth 407. Please click here to schedule a meeting with Axtria’s team at ISPOR 2024 and/or to learn more about our RWE and HEOR analytics solutions.
About Axtria's Products and Solutions
Axtria is proud to work with 16 of the top 20 life sciences companies, globally. From our roots as a trusted consultant to our status as one of the world’s leading providers of cloud-based pharmaceutical management software, Axtria has been powering the digital transformation of life sciences. Our experts call upon years of domain experience in the industry to guide pharma giants from brand launches to retirement. Our products go even further. Axtria InsightsMAx™ helps everyone from the C-suite to junior associates uncover trends to make better decisions. Axtria SalesIQ™ helps optimize field forces and provider engagements. Axtria CustomerIQ™ leverages AI-enabled next-best-action omnichannel choices. Axtria MarketingIQ™ turns investment analyses into pinpoint strategies. And Axtria DataMAx™ and DataMAx™ for Emerging Pharma is the data management framework that pulls it all together with best-in-class security and integration.